Shares of Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) fell 1.3% on Wednesday . The stock traded as low as $10.61 and last traded at $11.1760. 2,162 shares traded hands during trading, a decline of 64% from the average session volume of 6,077 shares. The stock had previously closed at $11.32.
Drugs Made in America Acquisition Trading Down 1.3%
The company has a 50 day moving average of $10.76 and a two-hundred day moving average of $10.60.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
See Also
- Five stocks we like better than Drugs Made in America Acquisition
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
